Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 1;36(1):153-155.
doi: 10.1097/QAD.0000000000003063.

Weight gain in treatment-naive HIV-1 infected patients starting abacavir/lamivudine/dolutegravir or tenofovir alafenamide/emtricitabine/bictegravir

Leonardo Calza  1 , Marco Borderi  1 , Vincenzo Colangeli  1 , Teresa Miani  1 , Bianca Nuti  1 , Isabella Bon  2 , Tiziana Lazzarotto  2 , Pierluigi Viale  1
Affiliations

Weight gain in treatment-naive HIV-1 infected patients starting abacavir/lamivudine/dolutegravir or tenofovir alafenamide/emtricitabine/bictegravir

Leonardo Calza et al. AIDS. .
No abstract available

PubMed Disclaimer

References

    1. Ruderman SA, Crane HM, Nance RM, Whitney BM, Harding BN, Mayer KH, et al. Brief report: weight gain following ART initiation in ART-naive people living with HIV in the current treatment era . J Acquir Immune Defic Syndr 2021; 86:339–343.
    1. Bourgi K, Jenkins CA, Rebeiro PF, Palella F, Moore RD, Altoff KN, et al. Weight gain among treatment-naive persons with HIV starting integrase inhibitors compared to nonnucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada . J Int AIDS Soc 2020; 23:e25484.
    1. Chow W, Donga P, Côté-Sergent A, Rossi C, Lefebvre P, Lafeuille MH, et al. An assessment of weight change associated with the initiation of a protease or integrase strand transfer inhibitor in patients with human immunodeficiency virus . Curr Med Res Opin 2020; 36:1313–1323.
    1. Menard A, Meddeb L, Tissot-Dupont H, Ravaux I, Dhiver C, Mokhtari S, et al. Dolutegravir and weight gain: an unexpected bothering side effect? . AIDS 2017; 31:1499–1500.
    1. Bourgi K, Rebeiro PF, Turner M, Castilho JL, Hulgan T, Raffanti SP, et al. Greater weight gain in treatment-naive persons starting dolutegravir-based antiretroviral therapy . Clin Infect Dis 2020; 70:1267–1274.

LinkOut - more resources